Business
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to
About this update from Autonomix Medical, Inc.
[{"type":"text","content":"Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer in Q1 CY2024 Cash runway to fund operations into Q1 CY2025 THE WOODLANDS, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, reported financial results yesterday for the third quarter FY2024 ended December 31, 2023 and provided a corporate update. Recent Highlights Closed $11.2 million in gross proceeds from initial public offering (“IPO”) and commenced trading on NASDAQ under the ticker symbol “AMIX”;Completed $8,000,000 all stock-based transaction for exclusive worldwide rights to technology for cardiology field use;Completed preclinical safety study to support program advancement into first in human clinical study to treat pancreatic cancer pain through transvascular ablation;Completed formation of engineering development team;Received Ethics Committee authorization for proof-of-concept (“PoC”) human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain; andLaunched corporate social media channels: X, LinkedIn, Instagram and Facebook. “I am incredibly pleased with the progress we have made on the corporate, financial and clinical fronts in such a short period of time. With the recent close of our IPO, subsequent listing onto NASDAQ, and advancing the development program for our potentially breakthrough technology, the Company is poised for an exciting year. We are grateful for the continued support and remain focused on successfully executing on the milestones laid out ahead of us,” commented Lori Bisson, Chief Executive Officer of Autonomix. “We believe that our technology has the potential to address the significant unmet need for patients with severe, chronic debilitating pain from pancreatic cancer, contributing to an exceptionally difficult quality of life, that currently is not well-treated by pharmacologic approaches. We continue to make solid progress with our PoC huma...